TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. Vandana Singh Mounjaro Maker Eli Lilly Taps ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

And when you're looking even further ahead, at the next five years, the valuation may be even more justifiable as Eli Lilly stock trades at a price/earnings-to-growth (PEG) multiple of around 0.75.

Going by what you pay per dollar of sales or profit, LLY stock looks very expensive compared to the broader market. Eli Lilly and has a price-to-sales (P/S) ratio of 16.6 vs. a figure of 2.8 for ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... for the next line of drugs front ran the stock price. For example, in 2016 Lilly was trading 13 times the trailing 12 months ...